As a therapeutic approach to treat IBD, Veiga et al. described the use of IL10-modified mRNA encapsulated in LNPs for cell-specific delivery into Ly6c+ inflammatory leukocytes in both in vitro and in vivo models [129]. Here, IL10 is linked to inflammatory bowel disease.